Skip to main content

Search

Reset all filters
640 Result(s)
Sort by

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
Our Commitment

Our Commitment

Combating counterfeits requires a globally-coordinated effort of all public and private stakeholders affected. On a corporate basis and locally we actively support those initiatives by associations, law-enforcement authorities and governments. These are d
Targeting HER2 in cancer

Targeting HER2 in cancer

Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.